Article
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
Journal of neuro-oncology - 1 Jun 2011
Gerstner Elizabeth R, Eichler April F, Plotkin Scott R, Drappatz Jan, Doyle Colin L, Xu Lei, Duda Dan G, Wen Patrick Y, Jain Rakesh K, Batchelor Tracy T
Abstract excerpt
Targeting angiogenesis in glioblastoma (GBM) may improve patient outcome by normalizing tumor vasculature and improving delivery of chemotherapeutics and oxygen. Consequently, concomitant administration of small molecule inhibitors of the VEGF pathway will likely have a positive impact on chemoradiation treatment outcome. We conducted a Phase I study of vatalanib, a small molecule inhibitor of VEGFR, PDGFR, and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.